Qiagen NV, the European molecular testing company, is reportedly close to naming Jonathan Pratt as its next Chief Executive Officer. This development coincides with the company actively exploring strategic options, including a potential sale, according to sources familiar with the matter. The supervisory board has been engaging in preliminary discussions with various interested parties, including several U.S. strategic buyers, in recent weeks.
The search for a new CEO began in November when Thierry Bernard announced his departure, a move analysts believe could facilitate a successful transaction. JPMorgan analyst Casey Woodring noted that Qiagen's profile is similar to Hologic Inc., which recently completed a private equity buyout at a 46% premium. Woodring suggested Danaher Corporation and Agilent Technologies Inc. as potential suitors due to their capacity for large acquisitions.
Jefferies analyst Tycho Peterson highlighted Qiagen's differentiated portfolio in digital PCR and latent TB testing as key drivers for a premium valuation. Peterson's sum-of-the-parts analysis indicated a potential takeout price around $60 per share, or 16x EBITDA, with a possibility of reaching the low- to mid-$60s (17x EBITDA) if multiple bidders emerge. This could translate to a deal worth over $13 billion.
Despite the significant surge in Qiagen's share price following the reports, some analysts remain cautious. UBS analyst Dan Leonard maintained a "Neutral" rating, citing a valuation spread between European and U.S.-listed companies as a challenge. He questioned whether the latest reports would materialize into a formal offer or if it would be another instance of unfulfilled speculation. Deutsche Bank analyst Jan Koch downgraded Qiagen's shares from "Buy" to "Hold" after the stock price surpassed his $52 price target, though he raised his firm's price target to $54.
